Real-world Survival, Healthcare Resource Utilization, and Costs among U.S. Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-GemOx in the Relapsed/Refractory Setting

Mahek Garg,Justin Puckett,Sachin Kamal-Bahl,Monika Raut,Katherine Elizabeth Ryland,Jalpa A. Doshi,Scott F. Huntington

DOI: https://doi.org/10.1016/j.clml.2024.01.010

2024-02-13

Abstract:Background Little recent real-world evidence exists on overall survival, healthcare resource utilization (HCRU), and costs among R/R DLBCL patients treated with the combination of rituximab, gemcitabine, and oxaliplatin (R-GemOx), a widely-used regimen for patients ineligible for stem cell transplant due to age or comorbidities. Patients and Methods This retrospective analysis used 2014-2019 U.S. Medicare claims. Individuals aged ≥66 years with a new DLBCL diagnosis between 10/01/2015 and 12/31/2018 and continuous fee-for-service Medicare Part A, B, and D coverage in the 12 months pre- and post-index were followed to identify the sample of patients with evidence of R-GemOx treatment in the second-line (2L) or third-line (3L) setting. Outcomes included overall survival, all-cause and DLBCL-related HCRU, and costs after R-GemOx initiation. Results The final sample included 157 patients who received treatment with R-GemOx in the R/R settings (mean (SD) age 77.5 (6.0) years, 39.5% age>80 years; 66.9% male; 91.1% White). Of these, 126 received R-GemOx in the 2L setting and 31 received R-GemOx in the 3L setting. Median overall survival from R-GemOx initiation was 6.9 months and 6.8 months in the 2L and 3L setting, respectively. Rates of all-cause hospitalization (68.1% [2L] and >90% [3L]) and hospice use (42.9% [2L] and 51.7% [3L]) were high in the 12 months after R-GemOx initiation. All-cause total costs were substantial ( 142,812 [3L]) and approximately 80% of costs were DLBCL-related within 12 months of R-GemOx initiation. Conclusion Elderly U.S. Medicare beneficiaries diagnosed with DLBCL who initiated R-GemOx treatment in the R/R setting have poor overall survival, high rates of HCRU, and substantial costs. MICRO- Medicare beneficiaries with DLBCL who initiated R-GemOx treatment in the relapsed/refractory (R/R) settings had poor overall survival, high rates of healthcare resource use, and substantial costs, underscoring the need for newer, more efficacious therapies for elderly patients with R/R DLBCL.

oncology,hematology